Re: Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer
I'm glad to see the CEO and Chairman position resolved with the hire of O'Day, who should bring a wealth of experience and leadership from his days at Roche. I've seen it said that he is not an scientist or clinician, as were Martin and Milligan, but rather holds an MBA. I see this as a plus, rather than a negative. GILD needs someone who is able to aggressively seek out business opportunities in the biotech area. Now perhaps the company can put its cash to work in the next M&A in 2019. That and the pipeline hopefully coming to fruition soon should return GILD to being a growth company in the near future. Not ready to jump in for more though until I see the numbers and guidance in the next earnings report.